Depression Pipeline Market Companies Involved in Therapeutics Development are AB Science SA, Acetylon Pharmaceuticals, Inc., Ache Laboratorios Farmaceuticos S/A, Adamed Sp. z o.o., Addex Therapeutics Ltd, Aequus Pharmaceuticals Inc., Alkermes Plc, Allergan Plc, Alvogen Korea Co., Ltd., Amorsa Therapeutics Inc., Anavex Life Sciences Corp., Angelini Group, Angita B.V., AstraZeneca Plc, Axsome Therapeutics, Inc., Azevan Pharmaceuticals, Inc., BioCrea GmbH, Biogen, Inc., Bionomics Limited, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Calico LLC, Cerecor Inc., Clera Inc., D-Pharm Ltd., Delpor, Inc., e-Therapeutics Plc, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline Plc, GliaCure Inc., H. Lundbeck A/S, Heptares Therapeutics Limited, HolsboerMaschmeyer NeuroChemie GmbH, Hua Medicine Ltd., Hyundai Pharmaceutical Co., Ltd., Impel NeuroPharma, Inc., INSYS Therapeutics, Inc., Intas Pharmaceuticals Ltd., Intra-Cellular Therapies, Inc., INVENT Pharmaceuticals, Inc., Johnson & Johnson, KemPharm, Inc., Lead Discovery Center GmbH, Les Laboratoires Servier SAS, Lixte Biotechnology Holdings, Inc., Luye Pharma Group Ltd., M et P Pharma AG, Mapi Pharma Ltd., Mapreg S.A.S., Meta-IQ ApS, Methylation Sciences Inc., MI.TO. Technology S.r.L., miCure Therapeutics Ltd., Mitsubishi Tanabe Pharma Corporation, Neuralstem, Inc., Neurocrine Biosciences, Inc., NeuroNascent, Inc., NeurOp, Inc, Newron Pharmaceuticals S.p.A., Nippon Chemiphar Co., Ltd., nLife Therapeutics, S.L., Novartis AG, Omeros Corporation, Otsuka Holdings Co., Ltd., Pfizer Inc., Pherin Pharmaceuticals, Inc., Polleo Pharma Limited, Protagenic Therapeutics Inc., Reviva Pharmaceuticals Inc., Richter Gedeon Nyrt., RTI International, Saniona AB, SK Biopharmaceuticals Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Supernus Pharmaceuticals, Inc., Suven Life Sciences Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Takeda Pharmaceutical Company Limited, Tetra Discovery Partners LLC, Trevena, Inc., TRImaran Pharma, Inc., Turing Pharmaceuticals AG, VistaGen Therapeutics , Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Zogenix, Inc. and Zysis Limited.
Get discount on this research at http://www.rnrmarketresearch.com/contacts/discount?rname=539813
The report provides comprehensive information on the therapeutics under development for Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Depression and features dormant and discontinued projects.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Complete research report of 508 pages with TOC is available at http://www.rnrmarketresearch.com/depression-pipeline-review-h1-2016-market-report.html
- The report provides a snapshot of the global therapeutic landscape of Depression
- The report reviews pipeline therapeutics for Depression by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Depression therapeutics and enlists all their major and minor projects
- The report assesses Depression therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Depression
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Depression
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Depression pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
RnR Market Research
RnRMarketResearch.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Connect with Us:
G+ / Google Plus: https://plus.google.com/104156468549256253075/posts
RSS / Feeds: http://www.rnrmarketresearch.com/feed
P: + 1 888 391 5441